Molgramostim (Savara Pharmaceuticals)

N/A

Report date: 2026/02/20 20:02:00

Base Information

Drug NameMolgramostim (Savara Pharmaceuticals)
Drug Alias Namerh-GM-CSFGM-CSF inhalation (Savara Pharmaceuticals)Nebulised recombinant human GM-CSF (Savara Pharmaceuticals)MolgradexMOLBREEVI +[7] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionGranulocyte-macrophage colony-stimulating factor receptor stimulants
TargetsGranulocyte-macrophage colony-stimulating factor receptor
Therapy Area/IndicationsRespiratory Distress Syndrome, AdultPulmonary Alveolar ProteinosisBronchiectasis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[23] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesSavara Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesSavara IncUniversity Of Giessen
Inactive CompaniesN/A
Active IndicationsRespiratory Distress Syndrome, AdultPulmonary Alveolar Proteinosis
Inactive IndicationsBronchiectasisCystic FibrosisMycobacterium Infections, Nontuberculous

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG